{"entity":{"type":"insider","cik":"0001817226","url":"/insider/0001817226","json_url":"/insider/0001817226.json","name":"Beaurang Pierre","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":21,"n_filings":7,"first":"2021-02-22","last":"2021-08-11","span_basis":"filed_date"},"name_variants":[{"name":"Beaurang Pierre","source":"filing","n_filings":7,"first_seen":"2021-02-22","last_seen":"2021-08-11"}],"transactions":[{"id":4670105,"accession":"0001209191-21-050976","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-050976","line_url":"/filing/0001209191-21-050976#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5620.0,"shares_display":"5,620","price_per_share":29.7382,"price_display":"29.74","price_state":"stated","total_value":167128.684,"total_display":"167,128.68","shares_owned_after":6210.0,"shares_owned_after_display":"6,210","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-10","filed_date":"2021-08-11","scope":"insider"},{"id":4670103,"accession":"0001209191-21-050976","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-050976","line_url":"/filing/0001209191-21-050976#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1880.0,"shares_display":"1,880","price_per_share":30.2113,"price_display":"30.21","price_state":"stated","total_value":56797.244,"total_display":"56,797.24","shares_owned_after":4330.0,"shares_owned_after_display":"4,330","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-10","filed_date":"2021-08-11","scope":"insider"},{"id":5293265,"accession":"0001209191-21-046362","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-046362","line_url":"/filing/0001209191-21-046362#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7100.0,"shares_display":"7,100","price_per_share":23.877,"price_display":"23.88","price_state":"stated","total_value":169526.7,"total_display":"169,526.70","shares_owned_after":4730.0,"shares_owned_after_display":"4,730","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-12","filed_date":"2021-07-12","scope":"insider"},{"id":5293260,"accession":"0001209191-21-046362","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-046362","line_url":"/filing/0001209191-21-046362#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":24.73,"price_display":"24.73","price_state":"stated","total_value":9892.0,"total_display":"9,892.00","shares_owned_after":4330.0,"shares_owned_after_display":"4,330","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-12","filed_date":"2021-07-12","scope":"insider"},{"id":4377099,"accession":"0001209191-21-039810","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-039810","line_url":"/filing/0001209191-21-039810#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6000.0,"shares_display":"6,000","price_per_share":29.1469,"price_display":"29.15","price_state":"stated","total_value":174881.4,"total_display":"174,881.40","shares_owned_after":5830.0,"shares_owned_after_display":"5,830","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-10","filed_date":"2021-06-11","scope":"insider"},{"id":4377096,"accession":"0001209191-21-039810","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-039810","line_url":"/filing/0001209191-21-039810#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1100.0,"shares_display":"1,100","price_per_share":30.0051,"price_display":"30.01","price_state":"stated","total_value":33005.61,"total_display":"33,005.61","shares_owned_after":4730.0,"shares_owned_after_display":"4,730","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-10","filed_date":"2021-06-11","scope":"insider"},{"id":4377093,"accession":"0001209191-21-039810","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-039810","line_url":"/filing/0001209191-21-039810#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":30.9037,"price_display":"30.90","price_state":"stated","total_value":12361.48,"total_display":"12,361.48","shares_owned_after":4330.0,"shares_owned_after_display":"4,330","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-10","filed_date":"2021-06-11","scope":"insider"},{"id":4892516,"accession":"0001209191-21-031891","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-031891","line_url":"/filing/0001209191-21-031891#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4299.0,"shares_display":"4,299","price_per_share":26.0683,"price_display":"26.07","price_state":"stated","total_value":112067.6217,"total_display":"112,067.62","shares_owned_after":7531.0,"shares_owned_after_display":"7,531","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-10","filed_date":"2021-05-11","scope":"insider"},{"id":4892509,"accession":"0001209191-21-031891","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-031891","line_url":"/filing/0001209191-21-031891#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2501.0,"shares_display":"2,501","price_per_share":26.8745,"price_display":"26.87","price_state":"stated","total_value":67213.1245,"total_display":"67,213.12","shares_owned_after":5030.0,"shares_owned_after_display":"5,030","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-10","filed_date":"2021-05-11","scope":"insider"},{"id":4892503,"accession":"0001209191-21-031891","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-031891","line_url":"/filing/0001209191-21-031891#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":700.0,"shares_display":"700","price_per_share":27.6621,"price_display":"27.66","price_state":"stated","total_value":19363.47,"total_display":"19,363.47","shares_owned_after":4330.0,"shares_owned_after_display":"4,330","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-10","filed_date":"2021-05-11","scope":"insider"},{"id":4619954,"accession":"0001209191-21-026457","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-026457","line_url":"/filing/0001209191-21-026457#line-5","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4072.0,"shares_display":"4,072","price_per_share":26.8284,"price_display":"26.83","price_state":"stated","total_value":109245.2448,"total_display":"109,245.24","shares_owned_after":7758.0,"shares_owned_after_display":"7,758","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-12","filed_date":"2021-04-13","scope":"insider"},{"id":4619951,"accession":"0001209191-21-026457","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-026457","line_url":"/filing/0001209191-21-026457#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2883.0,"shares_display":"2,883","price_per_share":27.669,"price_display":"27.67","price_state":"stated","total_value":79769.727,"total_display":"79,769.73","shares_owned_after":4875.0,"shares_owned_after_display":"4,875","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-12","filed_date":"2021-04-13","scope":"insider"},{"id":4619947,"accession":"0001209191-21-026457","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-026457","line_url":"/filing/0001209191-21-026457#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":545.0,"shares_display":"545","price_per_share":28.6549,"price_display":"28.65","price_state":"stated","total_value":15616.9205,"total_display":"15,616.92","shares_owned_after":4330.0,"shares_owned_after_display":"4,330","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-12","filed_date":"2021-04-13","scope":"insider"},{"id":4775382,"accession":"0001209191-21-018935","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-018935","line_url":"/filing/0001209191-21-018935#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4490.0,"shares_display":"4,490","price_per_share":37.306,"price_display":"37.31","price_state":"stated","total_value":167503.94,"total_display":"167,503.94","shares_owned_after":200.0,"shares_owned_after_display":"200","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-08","filed_date":"2021-03-09","scope":"insider"},{"id":4775378,"accession":"0001209191-21-018935","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-018935","line_url":"/filing/0001209191-21-018935#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2810.0,"shares_display":"2,810","price_per_share":36.4792,"price_display":"36.48","price_state":"stated","total_value":102506.552,"total_display":"102,506.55","shares_owned_after":4690.0,"shares_owned_after_display":"4,690","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-08","filed_date":"2021-03-09","scope":"insider"},{"id":4775372,"accession":"0001209191-21-018935","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-018935","line_url":"/filing/0001209191-21-018935#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":38.34,"price_display":"38.34","price_state":"stated","total_value":7668.0,"total_display":"7,668.00","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-08","filed_date":"2021-03-09","scope":"insider"},{"id":5035970,"accession":"0001209191-21-012661","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-21-012661","line_url":"/filing/0001209191-21-012661#line-8","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6400.0,"shares_display":"6,400","price_per_share":35.9888,"price_display":"35.99","price_state":"stated","total_value":230328.32,"total_display":"230,328.32","shares_owned_after":1400.0,"shares_owned_after_display":"1,400","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-18","filed_date":"2021-02-22","scope":"insider"},{"id":5035965,"accession":"0001209191-21-012661","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-21-012661","line_url":"/filing/0001209191-21-012661#line-7","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4553.0,"shares_display":"4,553","price_per_share":35.0217,"price_display":"35.02","price_state":"stated","total_value":159453.8001,"total_display":"159,453.80","shares_owned_after":7800.0,"shares_owned_after_display":"7,800","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-18","filed_date":"2021-02-22","scope":"insider"},{"id":5035961,"accession":"0001209191-21-012661","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-012661","line_url":"/filing/0001209191-21-012661#line-6","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2647.0,"shares_display":"2,647","price_per_share":34.188,"price_display":"34.19","price_state":"stated","total_value":90495.636,"total_display":"90,495.64","shares_owned_after":12353.0,"shares_owned_after_display":"12,353","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-18","filed_date":"2021-02-22","scope":"insider"},{"id":5035956,"accession":"0001209191-21-012661","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-012661","line_url":"/filing/0001209191-21-012661#line-5","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":36.924,"price_display":"36.92","price_state":"stated","total_value":36924.0,"total_display":"36,924.00","shares_owned_after":400.0,"shares_owned_after_display":"400","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-18","filed_date":"2021-02-22","scope":"insider"},{"id":5035953,"accession":"0001209191-21-012661","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-012661","line_url":"/filing/0001209191-21-012661#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817226","owner_name":"Beaurang Pierre","owner_url":"/insider/0001817226","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":37.875,"price_display":"37.88","price_state":"stated","total_value":15150.0,"total_display":"15,150.00","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-18","filed_date":"2021-02-22","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":21,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":21,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":21},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001549595","name":"Nurix Therapeutics, Inc.","url":"/issuer/0001549595","role":"Officer (Chief Business Officer)","n_filings":7,"first_seen":"2021-02-22","last_seen":"2021-08-11"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001817226","retrieved_at":"2026-08-21T12:16:13+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}